Efficacy of Repaglinide in Subjects With Type 2 Diabetes

Efficacy of Repaglinide Compared to Glyburide and Placebo on Hepatic Glucose Metabolism in Type 2 Diabetic Subjects Treated With Diet or With Antidiabetic Oral Agents. A Randomized, Open, Cross-over Single-centre Placebo-controlled Trial

This trial is conducted in Europe. The aim of this trial is to compare the efficacy of repaglinide to glyburide and placebo on hepatic glucose metabolism in subjects with type 2 diabetes.

Inclusion Criteria:

• Type 2 diabetes
• HbA1c (glycosylated haemoglobin A1c) above 7 %
• BMI (body mass index) below 32 kg/m^2
• FBG (fasting blood glucose) after wash out period 130-220 mg/dl
• Currently treated with diet or OHA (oral hypoglycaemic agent)

Exclusion Criteria:

• Current systemic treatment with concomitant medication
• Known or suspected history of drug or alcohol dependence
• Any other significant concomitant disease such as cerebrovascular or symptomatic peripheral vascular disease, malignant, disease or severe treated or untreated hypertension
• Hepatic disease
• Cardiac problems
• Active proliferative retinopathy
• Known or suspected allergy to trial product or related products
• Women in fertile age and women having the intention of becoming pregnant
• Body Mass Index (BMI) above 32 kg/m^2